VACBF
Price
$0.30
Change
+$0.03 (+11.11%)
Updated
May 15 closing price
Capitalization
83.57M
ZBIO
Price
$11.43
Change
-$0.02 (-0.17%)
Updated
May 23, 02:13 PM (EDT)
Capitalization
479M
Interact to see
Advertisement

VACBF vs ZBIO

Header iconVACBF vs ZBIO Comparison
Open Charts VACBF vs ZBIOBanner chart's image
NYKODE THERAPEUTICS AS
Price$0.30
Change+$0.03 (+11.11%)
Volume$8.3K
Capitalization83.57M
Zenas Biopharma
Price$11.43
Change-$0.02 (-0.17%)
Volume$200
Capitalization479M
VACBF vs ZBIO Comparison Chart
Loading...
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
VACBF vs. ZBIO commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VACBF is a Hold and ZBIO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (VACBF: $0.30 vs. ZBIO: $11.45)
Brand notoriety: VACBF and ZBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: VACBF: 560% vs. ZBIO: 46%
Market capitalization -- VACBF: $83.57M vs. ZBIO: $479M
VACBF [@Biotechnology] is valued at $83.57M. ZBIO’s [@Biotechnology] market capitalization is $479M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

VACBF’s FA Score shows that 1 FA rating(s) are green whileZBIO’s FA Score has 0 green FA rating(s).

  • VACBF’s FA Score: 1 green, 4 red.
  • ZBIO’s FA Score: 0 green, 5 red.
According to our system of comparison, both VACBF and ZBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ZBIO’s TA Score shows that 5 TA indicator(s) are bullish.

  • ZBIO’s TA Score: 5 bullish, 4 bearish.

Price Growth

VACBF (@Biotechnology) experienced а 0.00% price change this week, while ZBIO (@Biotechnology) price change was +17.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.71%. For the same industry, the average monthly price growth was +2.75%, and the average quarterly price growth was -2.89%.

Reported Earning Dates

ZBIO is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+0.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZBIO($479M) has a higher market cap than VACBF($83.6M). ZBIO YTD gains are higher at: 39.805 vs. VACBF (24.834). VACBF has higher annual earnings (EBITDA): -43.07M vs. ZBIO (-163.75M). ZBIO has more cash in the bank: 351M vs. VACBF (115M). ZBIO has less debt than VACBF: ZBIO (1M) vs VACBF (3.44M). VACBF has higher revenues than ZBIO: VACBF (8.68M) vs ZBIO (5M).
VACBFZBIOVACBF / ZBIO
Capitalization83.6M479M17%
EBITDA-43.07M-163.75M26%
Gain YTD24.83439.80562%
P/E RatioN/AN/A-
Revenue8.68M5M174%
Total Cash115M351M33%
Total Debt3.44M1M343%
TECHNICAL ANALYSIS
Technical Analysis
ZBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ZBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FOSKX72.27N/A
N/A
Fidelity Overseas K
SCCUX10.77N/A
N/A
Invesco Income Advantage U.S. Fund C
FASOX45.50N/A
N/A
Fidelity Advisor Value Strategies I
GEBSX10.81N/A
N/A
Goldman Sachs ESG Em Mkts Eq R6
AFVLX21.44N/A
N/A
Applied Finance Select Investor

VACBF and

Correlation & Price change

A.I.dvisor tells us that VACBF and EYEN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VACBF and EYEN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VACBF
1D Price
Change %
VACBF100%
N/A
EYEN - VACBF
32%
Poorly correlated
+45.00%
SPHRY - VACBF
27%
Poorly correlated
N/A
RVPH - VACBF
22%
Poorly correlated
N/A
ZBIO - VACBF
21%
Poorly correlated
+4.66%
BPTSY - VACBF
20%
Poorly correlated
-18.27%
More

ZBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with REPL. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZBIO
1D Price
Change %
ZBIO100%
+4.66%
REPL - ZBIO
35%
Loosely correlated
+3.55%
SNDX - ZBIO
32%
Poorly correlated
+1.50%
KURA - ZBIO
30%
Poorly correlated
+0.65%
CRNX - ZBIO
30%
Poorly correlated
+0.53%
TIL - ZBIO
30%
Poorly correlated
+51.73%
More